Accessing Library
Connecting to Pep Nation Lab's research database...
Connecting to Pep Nation Lab's research database...
Select Up To Four Compounds To Review Their Evidence, Targets, And Handling Side By Side.
For Laboratory Research Only
| Attribute | ||
|---|---|---|
Research Summary | Ipamorelin is the cleanest growth hormone booster. It gently nudges your brain to release growth hormone without making you hungry or raising your stress hormones. It is perfect for steady, long-term anti-aging. | GHRP-6 tells the brain to release growth hormone, but it also flips the "extreme hunger" switch. It makes the body want to eat heavily, making it a top choice for gaining weight and building mass. |
Studied For | GH secretagogue researchAnti-aging / longevity via GH axisBody composition improvementLean muscle gainFat loss via GHSleep quality / GH rhythmRecoveryBone density via GHIGF-1 elevationPulsatile GH release simulationStacked with CJC-1295 (no DAC)GI motility researchMetabolic rate improvementCollagen synthesis via GHAthletic performanceanti-agingmuscle growthfat lossrecoverydeep sleepbone densitycellular repairGH pulse stimulation | GH release stimulationAppetite stimulation / hunger researchGI motility researchGH secretagogue researchIGF-1 elevationMuscle growth via GH axisFat loss via GHBody composition researchGhrelin axis signalingPituitary GH function testingAnti-aging via GHGastric motility and emptyingCytoprotective GI effectsGH pulse amplitude researchLean mass increaseappetite stimulationgrowth hormone secretagoguegastric motilitymuscle growthrecovery |
Research Areas | Performance & MuscleLongevityMetabolicJoint & Bone SupportSleep & Circadian | Performance & MuscleMetabolicGut Health & GI Repair |
Best Stacked With | cjc-1295-no-dacsermorelinghrp-2bac-water | cjc-1295-no-dacsermorelinbac-water |
Overview | ||
Category | Muscle Growth & Performance | Muscle Growth & Performance |
Compound Class | Selective synthetic pentapeptide GH secretagogue (GHRP); minimal cortisol/prolactin side effects | Synthetic hexapeptide GH secretagogue (GHRP); first-generation ghrelin mimetic |
Molecular Target | GHS-R1a (ghrelin receptor) agonist; highly selective for pituitary GH release without significant ACTH/cortisol elevation | GHS-R1a (ghrelin receptor) agonist; stimulates pituitary GH release and endogenous ghrelin; strong appetite/hunger signal |
Aliases / AKA | NNC 26-0161NNC26-0161Ipamorelin acetateGHRP-1a analogSelective GHRPIpamorelin peptide | GHRP6Growth Hormone Releasing HexapeptideGHRP-6 peptideHis-D-Trp-Ala-Trp-D-Phe-Lys-NH2GH-releasing hexapeptideGrowth hormone secretagogue hexapeptide |
Parent Compound | Ghrelin mimetic | Ghrelin mimetic |
Molecular Weight | 711.85 Da | 873.01 Da |
Amino Acid Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 |
CAS Number | 170851-70-4 | 87616-84-0 |
Year Discovered | Not Listed | Not Listed |
Pro-Angiogenic | No | No |
GLP-1 Class | No | No |
Purity | Not Listed | Not Listed |
Identity | ||
Evidence Tier | ||
Risk Level | ||
PubMed Citations | 1,192,840 Extensive | 808 Good |
Clinical Trials | Not Listed | Not Listed |
Regulatory Status | Not FDA-approved; research chemical; WADA S2. | Not FDA-approved; research chemical; WADA S2. |
Evidence & Regulatory | ||
Half-Life | ~2 hours | ~2.5 hours |
Typical Frequency | Not Listed | Not Listed |
Administration Route | Injection Only | Injection Only |
Mechanism / PK | Not Listed | Not Listed |
Reported Findings | Preclinical work established growth-hormone release with no rise in cortisol or prolactin. A human GI-motility program was run and discontinued for non-safety reasons. | Human studies show dose-dependent growth-hormone release and GHRH synergy; animal data suggest cardioprotection. Mostly mechanistic; no approved indication. |
Side Effects Noted | Best tolerated of the GHRPs; injection-site reactions, flushing, headache, mild water retention; limited human data. | Pronounced appetite increase; dose-dependent cortisol and prolactin elevation; flushing, fatigue, water retention. |
Warnings | Not approved; growth-hormone-axis risks apply with sustained use. WADA-prohibited. Research use only. | Not approved; growth-hormone-axis risks apply. WADA-prohibited. Research use only. |
Pharmacology | ||
Form | lyophilized | lyophilized |
Diluent | bacteriostatic or sterile water | bacteriostatic or sterile water |
Storage Temp | cold, dark | cold, dark |
Light Sensitive | Yes | Yes |
Freeze / Thaw | avoid | avoid |
Handling Notes | Most selective GHRP; often paired with a GHRH analog. | Strongest hunger effect of the common GHRPs. |
Reconstituted Shelf Life | 28 Days Refrigerated | 28 Days Refrigerated |
Handling & Storage | ||
Pep Nation Lab's comparison tool puts research-grade peptides and compounds head to head - mechanism of action, molecular target, evidence tier, molecular weight, sequence, half-life, and documented research focus - so qualified researchers can evaluate the differences that matter. Every data point is drawn from a referenced monograph. For in vitro laboratory research use only.
The two most-studied research peptides for tissue repair and recovery.
Single GLP-1 versus dual GLP-1/GIP incretin agonists in metabolic research.
Dual versus triple incretin receptor agonists in weight-research models.
A GLP-1 agonist versus a triple-agonist incretin in metabolic research.
A GHRH analog versus a selective ghrelin-receptor secretagogue.
A ghrelin-receptor secretagogue versus a GHRH analog for growth-hormone research.
Two GHRH analogs studied on the growth-hormone axis.
The two first-generation growth-hormone releasing peptides.
An amylin analog versus a GLP-1 agonist in metabolic research.
A mitochondrial-derived peptide versus an HGH fragment in metabolic research.
Melanocortin versus kisspeptin pathways in reproductive research.
A telomerase-pathway peptide versus NAD+ metabolism in longevity research.
A potent versus a highly selective ghrelin-receptor secretagogue.
Two GHRH analogs with contrasting half-life profiles.
A direct IGF-1 analog versus a growth-hormone secretagogue.
The DAC versus non-DAC forms of the CJC-1295 GHRH analog.
Two Russian-developed nootropic and anxiolytic research peptides.
Two mitochondrial-targeted peptides in cellular-energy research.
Two immune-modulating research peptides with distinct mechanisms.
Two HGH-fragment analogs studied for fat-metabolism research.
Next-generation multi-receptor incretin agonists in metabolic research.
Two leading tissue-repair peptides with distinct healing mechanisms.
A systemic repair peptide versus a copper peptide for tissue and skin research.
A GHRH analog versus a selective ghrelin-receptor secretagogue on the GH axis.
A dual incretin agonist versus an amylin analog in metabolic research.
A triple incretin agonist versus an amylin analog in weight research.
Two metabolic research compounds targeting mitochondrial and NNMT pathways.
NAD+ metabolism versus a mitochondrial-derived peptide in longevity research.
Two copper research peptides studied for skin and hair.
A long-acting versus a short-acting GHRH analog.
A selective versus a first-generation ghrelin-receptor secretagogue.
A GLP-1 agonist versus a GLP-1/amylin combination in metabolic research.
Two peptides studied for gut and mucosal repair.
Melanocortin versus oxytocin pathways in intimacy and libido research.
Two thymic immune-modulating research peptides.
An anxiolytic nootropic versus a sleep-associated research peptide.
Direct IGF-1 signaling versus myostatin inhibition in muscle research.
A mitochondrial-targeted peptide versus NAD+ in cellular-energy research.
Browse the full research catalog or the A To Z index to compare any compound.
Any research-grade compound in the library can be placed side by side - up to four at a time. The tool compares mechanism of action, molecular target, evidence tier, molecular weight, amino acid sequence, reported half-life, and what each compound has been studied for, all drawn from referenced monographs.
The evidence tier reflects how extensively a compound has been studied in the referenced literature, from early preclinical signals through to compounds with human clinical data. It is a research-quality signal only, never a safety or efficacy endorsement.
Each comparison page is generated from the same referenced compound database - a genuine side-by-side of mechanism, identity, pharmacokinetics, and evidence, plus data-derived key differences. They are curated, not auto-generated thin pages.
No. Every comparison is for in vitro laboratory research use only. Nothing here is medical advice, a treatment recommendation, or dosing guidance, and no product is for human or animal consumption.
